Charles Schwab Investment Management Inc. Has $142.53 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Charles Schwab Investment Management Inc. boosted its position in Moderna, Inc. (NASDAQ:MRNA) by 4.1% in the third quarter, Holdings Channel.com reports. The firm owned 2,132,777 shares of the company’s stock after purchasing an additional 83,082 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Moderna were worth $142,533,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in MRNA. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Moderna by 11.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after buying an additional 167,596 shares during the period. Dimensional Fund Advisors LP increased its position in Moderna by 2.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after acquiring an additional 29,566 shares during the period. ARK Investment Management LLC raised its stake in shares of Moderna by 10.4% during the third quarter. ARK Investment Management LLC now owns 1,163,946 shares of the company’s stock valued at $77,787,000 after acquiring an additional 109,852 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Moderna by 0.3% during the third quarter. Swiss National Bank now owns 966,800 shares of the company’s stock worth $64,611,000 after purchasing an additional 3,200 shares during the period. Finally, National Pension Service grew its position in shares of Moderna by 10.3% in the 3rd quarter. National Pension Service now owns 813,893 shares of the company’s stock valued at $54,392,000 after buying an additional 75,817 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 2,930 shares of company stock worth $217,170. 15.70% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on MRNA shares. Wolfe Research initiated coverage on shares of Moderna in a research report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target on the stock. Barclays lowered their price objective on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Berenberg Bank began coverage on Moderna in a research report on Tuesday, November 19th. They set a “hold” rating and a $42.00 target price on the stock. Piper Sandler reiterated an “overweight” rating and issued a $69.00 target price (down from $115.00) on shares of Moderna in a report on Monday, November 18th. Finally, Oppenheimer cut Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Moderna has an average rating of “Hold” and a consensus price target of $84.00.

Moderna Stock Performance

NASDAQ MRNA opened at $41.11 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company has a fifty day moving average price of $54.96 and a 200-day moving average price of $93.90. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47. The firm has a market cap of $15.82 billion, a price-to-earnings ratio of -7.06 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the business posted ($1.39) EPS. As a group, equities research analysts predict that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.